235 related articles for article (PubMed ID: 6980492)
1. Development of long-term cell lines and lymphoid clones reactive against murine and human tumors: a new approach to the adoptive immunotherapy of cancer.
Rosenberg SA; Eberlein TJ; Grimm EA; Lotze MT; Mazumder A; Rosenstein M
Surgery; 1982 Aug; 92(2):328-36. PubMed ID: 6980492
[TBL] [Abstract][Full Text] [Related]
2. [Effects of TCGF (T-cell growth factor) on experimental malignant glioma-specific killer T-cell].
Yamasaki T; Yamashita J; Handa H; Namba Y; Hanaoka M
No Shinkei Geka; 1984 Feb; 12(2):141-50. PubMed ID: 6609319
[TBL] [Abstract][Full Text] [Related]
3. Adoptive immunotherapy of a newly induced sarcoma: immunologic characteristics of effector cells.
Shu S; Rosenberg SA
J Immunol; 1985 Oct; 135(4):2895-903. PubMed ID: 2411817
[TBL] [Abstract][Full Text] [Related]
4. Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy.
Shu SY; Chou T; Rosenberg SA
J Immunol; 1987 Jul; 139(1):295-304. PubMed ID: 2953816
[TBL] [Abstract][Full Text] [Related]
5. In vitro sensitization and expansion with viable tumor cells and interleukin 2 in the generation of specific therapeutic effector cells.
Shu S; Chou T; Rosenberg SA
J Immunol; 1986 May; 136(10):3891-8. PubMed ID: 3486223
[TBL] [Abstract][Full Text] [Related]
6. Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor.
Lotze MT; Grimm EA; Mazumder A; Strausser JL; Rosenberg SA
Cancer Res; 1981 Nov; 41(11 Pt 1):4420-5. PubMed ID: 6975652
[TBL] [Abstract][Full Text] [Related]
7. Allo-Ia reactive murine T-cell lines. II. Mechanisms of clonal expansion of T cells explored by use of the allo-Ia reactive T cell clones.
Narimatsu H; Saito K
J Immunol; 1983 Jul; 131(1):37-44. PubMed ID: 6190916
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2.
Rosenberg SA
J Biol Response Mod; 1984 Oct; 3(5):501-11. PubMed ID: 6389777
[TBL] [Abstract][Full Text] [Related]
9. Curative intravenous adoptive immunotherapy of Meth A murine sarcoma. A histologic and immunohistochemical assessment.
Reichert CM; Rosenstein M; Von Glatz J; Hsu SM; Rosenberg SA
Lab Invest; 1985 Mar; 52(3):304-13. PubMed ID: 3974201
[TBL] [Abstract][Full Text] [Related]
10. In vitro growth of murine T cells. V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors.
Yron I; Wood TA; Spiess PJ; Rosenberg SA
J Immunol; 1980 Jul; 125(1):238-45. PubMed ID: 6966652
[TBL] [Abstract][Full Text] [Related]
11. Antigen-dependent proliferation of cloned continuous lines of H-2-restricted influenza virus-specific cytotoxic T lymphocytes.
Andrew ME; Braciale TJ
J Immunol; 1981 Sep; 127(3):1201-4. PubMed ID: 6167621
[TBL] [Abstract][Full Text] [Related]
12. The immunological basis of tumor rejection: the absolute dependence of the effector arm on sensitized T cells after chemoimmunotherapy of a murine sarcoma.
Evans R; Duffy T
J Immunol; 1985 Jun; 134(6):4255-60. PubMed ID: 3872913
[TBL] [Abstract][Full Text] [Related]
13. Effect of Nocardia rubra cell wall skeleton on T-cell-mediated cytotoxicity in mice bearing syngeneic sarcoma.
Kawase I; Uemiya M; Yoshimoto T; Ogura T; Hirao F; Yamamura Y
Cancer Res; 1981 Feb; 41(2):660-6. PubMed ID: 6969630
[TBL] [Abstract][Full Text] [Related]
14. The systemic administration of purified interleukin 2 enhances the ability of sensitized murine lymphocytes to cure a disseminated syngeneic lymphoma.
Donohue JH; Rosenstein M; Chang AE; Lotze MT; Robb RJ; Rosenberg SA
J Immunol; 1984 Apr; 132(4):2123-8. PubMed ID: 6607956
[TBL] [Abstract][Full Text] [Related]
15. Adoptive immunotherapy of newly induced murine sarcomas.
Shu SY; Rosenberg SA
Cancer Res; 1985 Apr; 45(4):1657-62. PubMed ID: 3872168
[TBL] [Abstract][Full Text] [Related]
16. [Tumor-specific cytotoxicity of tumor infiltrating lymphocytes (TIL) induced with TCGF in murine mammary carcinoma].
Hori T; Kan N; Ohgaki K; Yamazaki N; Nakayama N; Nio Y; Inamoto T
Nihon Geka Gakkai Zasshi; 1984 Aug; 85(8):749-57. PubMed ID: 6238229
[TBL] [Abstract][Full Text] [Related]
17. Continuous cytotoxic T cell lines reactive against murine plasmacytoma tumor-associated antigens.
Giorgi JV; Warner NL
J Immunol; 1981 Jan; 126(1):322-30. PubMed ID: 6161166
[TBL] [Abstract][Full Text] [Related]
18. Expansion of autorecognitive cytotoxic effectors in human cancer by T cell growth factor (Interleukin 2)1.
Vose BM
Arch Geschwulstforsch; 1981; 51(4):317-26. PubMed ID: 6459065
[TBL] [Abstract][Full Text] [Related]
19. Tumor-infiltrating lymphocytes cultured in recombinant interleukin-2: enhancement of growth, cytotoxicity, and phenotypic expression of cytotoxic T-cell antigens by cyclophosphamide given intravenously prior to tumor harvest.
Lafreniere R; Borkenhagen K; Bryant LD; Ng E
J Biol Response Mod; 1989 Jun; 8(3):238-51. PubMed ID: 2787392
[TBL] [Abstract][Full Text] [Related]
20. Stimulation of host resistance against tumors by glycyrrhizin, an active component of licorice roots.
Suzuki F; Schmitt DA; Utsunomiya T; Pollard RB
In Vivo; 1992; 6(6):589-96. PubMed ID: 1296807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
